Risk stratification in luminal-type breast cancer: Comparison of Ki-67 with EndoPredict test results

Abstract This study aimed to validate the Clinical Treatment Score post-5 years (CTS5)-based risk stratification in a cohort comprising pre- and postmenopausal patients with estrogen receptor (ER)–positive breast cancer. We investigated the clinicopathologic parameters including Ki-67 labelling index (LI) to identify factors affecting late distant recurrence (DR). Women with ER-positive breast cancer who were free of DR for 5 years were identified between January 2004 and December 2009. We investigated the risk of late DR (5–10 years) according to the CTS5 risk group. Cox regression analysis was used to determine the prognostic performance of CTS5 and identify factors associated with late DR. In all, 680 women were included. Of these, 379 (55.7%) were premenopausal and 301 (44.3%) were postmenopausal. At a median follow-up of 118 months, 32 women had late DR. CTS5 was a significant prognostic factor for late DR in both pre- and postmenopausal women. In the low CTS5 group, high Ki-67 LI (> 20%) was a significant risk factor for late DR. CTS5 is a useful tool for assessing the risk of late DR in pre- and postmenopausal women with ER-positive breast cancer. Extended endocrine therapy can be considered in patients with high Ki-67 LI (> 20%) in the low CTS5 group.

Download Full-text

Association Between Shear Wave Elastography of Virtual Touch Tissue Imaging Quantification Parameters and the Ki‐67 Proliferation Status in Luminal‐Type Breast Cancer

Journal of Ultrasound in Medicine ◽

10.1002/jum.14663 ◽

2018 ◽

Vol 38 (1) ◽

pp. 73-80 ◽

Cited By ~ 1

Author(s):

Yubo Liu ◽

Yini Huang ◽

Jing Han ◽

Jianwei Wang ◽

Fei Li ◽

...

Keyword(s):

Breast Cancer ◽

Shear Wave ◽

Shear Wave Elastography ◽

Tissue Imaging ◽

Ki 67 ◽

Luminal Type ◽

Virtual Touch Tissue Imaging

Download Full-text

Ki-67 and Cyclin D1 in subtypes of triple-negative breast cancer with different androgen profiles.

Journal of Clinical Oncology ◽

10.1200/jco.2019.37.15_suppl.e12552 ◽

2019 ◽

Vol 37 (15_suppl) ◽

pp. e12552-e12552 ◽

Cited By ~ 1

Author(s):

Larisa N. Vashchenko ◽

Nikolay S. Karnaukhov ◽

Tatiana N. Gudtskova ◽

Mramza V. Kvarchiya ◽

Elena A. Karnaukhova ◽

...

Keyword(s):

Breast Cancer ◽

Cyclin D1 ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Test Results ◽

Ki 67 ◽

Cyclin Dependent Kinases ◽

The Difference ◽

Student’S T ◽

High Cyclin

e12552 Background: The purpose of the study was to analyze Ki-67 and Cyclin D1 expression in subtypes of triple negative breast cancer (TNBC) with different androgen profiles. Methods: Tissues of 60 patients with verified TNBC (T1N1M0/T2N0M0, ER-/PR-/Her2-) were studied. Immunohistochemical staining was performed with antibodies to androgen receptors (AR), CK5/6, Ki-67, Cyclin D1, and EGFR. Basal-like (BL) subtype was identified when > 25% cells were CK5/6+ and/or EGFR+ (any staining). Tumors with ≥10% positively stained cells were considered AR+. Parametric statistical methods were used. Significance of the difference between the two means was assessed by the Student's t-test. Results: BL TNBC showed significantly higher Ki-67 expression (81.9±3.1%), compared to other subtypes (70.8±3.1%), p < 0.05. A number of TNBC samples demonstrated Cyclin D1 overexpression ( > 30% stained cells) with no correlation with Ki-67 expression (r = 0.12). High Cyclin D1 levels were less common in BL TNBC (32.4% tumors), compared to other subtypes (43.5% tumors), but its average values were significantly higher (89.9±4.7% vs. 66.5±6.6%, p < 0.05). AR+ tumors were observed in 11 cases (18.3%). Levels of Ki-67 were similar in TNBC with different AR profiles. The percentage of BL tumors was similar in AR+ and AR- cancers (63.6% and 61.3%, respectively). Expression of Cyclin D1 was more frequent in AR+ TNBC (45.5%), vs. 34.7% in АR-. Average levels of Cyclin D1 were significantly higher in AR+ tumors (51.8±13.7%), vs. AR- (31.6±5.1%). Conclusions: TNBC differs in the Cyclin D1 leves; some tumors show its overexpression. Inhibition of cyclin-dependent kinases blocks the cell cycle, which may be useful in the TNBC treatment, which currently has no targets for therapy.

Download Full-text

Abstract P5-02-03: A comparison of the hot spot and the average cancer cell counting methods and the optimal cut-off point of the Ki-67 index for luminal type breast cancer with or without recurrence – A case control study for prognostic factors

10.1158/1538-7445.sabcs14-p5-02-03 ◽

2015 ◽

Author(s):

Nobuyuki Arima ◽

Reiki Nishimura ◽

Tomofumi Osako ◽

Yasuyuki Nishiyama ◽

Yasuhiro Okumura ◽

...

Keyword(s):

Breast Cancer ◽

Prognostic Factors ◽

Case Control Study ◽

Hot Spot ◽

Case Control ◽

Cell Counting ◽

Ki 67 ◽

Counting Methods ◽

Luminal Type ◽

Control Study

Download Full-text

Ki-67 expression in luminal type breast cancer and its association with the clinicopathology of the cancer

Oncology Letters ◽

10.3892/ol.2016.4199 ◽

2016 ◽

Vol 11 (3) ◽

pp. 2101-2105 ◽

Cited By ~ 5

Author(s):

PENG YUAN ◽

BENLING XU ◽

CHENGZHENG WANG ◽

CHENGJUAN ZHANG ◽

MIAOMIAO SUN ◽

...

Keyword(s):

Breast Cancer ◽

Ki 67 ◽

Luminal Type

Download Full-text

Ki-67 and p53 as Prognostic Factors for Luminal Type Breast Cancer

Journal of Breast Disease ◽

10.14449/jbd.2013.1.3 ◽

2013 ◽

Vol 1 (1) ◽

pp. 21-27 ◽

Cited By ~ 1

Author(s):

Ki Ho Kim ◽

Byung Joo Chae ◽

Byung Joo Song ◽

Sang Seol Jung

Keyword(s):

Breast Cancer ◽

Prognostic Factors ◽

Ki 67 ◽

Luminal Type

Download Full-text

A Comparison of the Hot Spot and the Average Cancer Cell Counting Methods and the Optimal Cutoff Point of the Ki-67 Index for Luminal Type Breast Cancer

Oncology ◽

10.1159/000441525 ◽

2015 ◽

Vol 90 (1) ◽

pp. 43-50 ◽

Cited By ~ 7

Author(s):

Nobuyuki Arima ◽

Reiki Nishimura ◽

Tomofumi Osako ◽

Yasuyuki Nishiyama ◽

Mamiko Fujisue ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Cell ◽

Hot Spot ◽

Cutoff Point ◽

Cell Counting ◽

Optimal Cutoff ◽

Ki 67 ◽

Counting Methods ◽

Luminal Type ◽

Optimal Cutoff Point

Download Full-text

Correlation between Ki-67 proliferation index in invasive breast cancer and molecular signatures: EndoPredict and MammaPrint

10.21203/rs.3.rs-452096/v1 ◽

2021 ◽

Author(s):

J. Eduardo Amezcua-Gálvez ◽

Carlos A. Lopez-Garcia ◽

Villarreal-Garza Cynthia ◽

Lopez-Rivera Victor ◽

Canavati-Marcos Mauricio ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Risk Stratification ◽

Invasive Breast Cancer ◽

Histological Grade ◽

Area Under The Curve ◽

Molecular Signature ◽

Proliferation Index ◽

Molecular Signatures ◽

Ki 67

Abstract Background: The need to identify patients with hormone receptor-positive (HR+) early invasive breast cancer (EIBC) who could benefit from adjuvant chemotherapy has been enhanced with the development of molecular signature tests. However, due to their high cost and limited availability alternative low-cost prognostic and predictive tests are used in clinical practice. Here, we sought to evaluate the performance of the proliferation marker Ki-67 to identify these patients and explore its association with molecular signatures and risk stratification markers. Methods: From our prospectively maintained multicenter breast cancer registry, we identified EIBC HR+ patients tested with EndoPredict or MammaPrint and Ki-67 as part of their routine workup. Patients were categorized into two groups: Group 1 (2016-2018) was evaluated using EndoPredict and Group 2 (2011 to 2018) with MammaPrint. A ≥20% Ki67 cutoff was utilized for identify high proliferative EIBC and a receiver-operative curve area under the curve (AUC) and kappa concordance were utilized to evaluate the performance of Ki-67 compared to molecular signature tests. Results: In the EndoPredict group, 54/96 patients were considered high-risk by EPclin. 57/96 patients had a Ki-67 ≥20%. However, there was no significant overall concordance between them (59.37%, κ = 0.168, p=0.09). In the MammaPrint group, 21/70 patients were considered high-risk. Ki67 ≥20% was present in 36 patients with a significant overall concordance (67.14%, κ 0.35, p<0.001). Additionally, Ki-67 was associated with the Nottingham histological grade (NHG) in both groups. Conclusion: There is a fair concordance between Ki-67 and MammaPrint risk stratification of HR + EIBC and no concordance with EndoPredict molecular signature. Cost-effectiveness analysis of these tests in developing countries are needed, until then, the use of Ki-67 seems reasonable to aid clinical decision.

Download Full-text